VIDEO: Michael C. Honigberg, MD, MPP, discusses bone marrow abnormality linked to CVD
Click Here to Manage Email Alerts
PHILADELPHIA — In this Healio video exclusive, Michael C. Honigberg, MD, MPP, discusses the latest research on clonal hematopoiesis of indeterminate potential in blood cells, an emerging risk factor for CVD.
Clonal hematopoiesis of indeterminate potential, also known as CHIP, is perhaps best described as a “pre-pre-pre blood cancer state,” Honigberg, a cardiologist and researcher at Massachusetts General Hospital and instructor of medicine at Harvard Medical School, said at the American Heart Association Scientific Sessions.
“While many people with CHIP mutations do not go on to develop blood cancer, emerging data suggest people with CHIP mutations have a 40% increased risk for all-cause mortality, with a lot of that excess risk explained by CVD,” Honigberg said.
Honigberg and his team are also studying CHIP’s potential ability to predict atrial fibrillation as well CHIP and risk for HF with preserved ejection fraction, an area where more therapies are still needed.
“CHIP-focused precision therapeutics could be an attractive future option for treating HFpEF in people with CHIP and HFpEF, and you’ll be hearing more about this in the coming years,” Honigberg said.
Watch the video for more.
References:
- Honigberg MC, et al. Abstract MDP143.
- Saadatagah S, et al. Abstract Su1101.
- Schuermans A, et al. Abstract Su1098. All presented at: American Heart Association Scientific Sessions; Nov. 11-13, 2023; Philadelphia.
Collapse
Healio Interviews
Click Here to Manage Email Alerts